Herpes simplex viruses -- more commonly known as herpes -- are categorized into two types: herpes type 1 (HSV-1, or oral herpes) and herpes type 2 (HSV-2, or genital herpes). Most commonly, herpes type 1 causes sores around the mouth and lips (sometimes called fever blisters or cold sores). HSV-1 can cause genital herpes, but most cases of genital herpes are caused by herpes type 2. In HSV-2, the infected person may have sores around the genitals or rectum. Although HSV-2 sores may occur in other locations, these sores usually are found below the waist.
What Causes Herpes Infections and Outbreaks?
Herpes simplex type 1, which is transmitted through oral secretions or sores on the skin, can be spread through kissing or sharing objects such as toothbrushes or eating utensils. In general, a person can only get herpes type 2 infection during sexual contact with someone who has a genital HSV-2 infection. It is important to know that both HSV-1 and HSV-2 can be spread even if sores are not present.
Pregnant women with genital herpes should talk to their doctor, as genital herpes can be passed on to the baby during childbirth.
For many people with the herpes virus, which can go through periods of being dormant, attacks (or outbreaks) can be brought on by the following conditions:
What Are the Symptoms of Herpes Simplex?
Symptoms of herpes simplex virus typically appear as a blister or as multiple blisters on or around affected areas -- usually the mouth, genitals, or rectum. The blisters break, leaving tender sores.
How Is Herpes Simplex Diagnosed?
Often, the appearance of herpes simplex virus is typical and no testing is needed to confirm the diagnosis. If a health care provider is uncertain, herpes simplex can be diagnosed with lab tests, including DNA -- or PCR -- tests and virus cultures.
How Is Herpes Simplex Treated?
Although there is no cure for herpes, treatments can relieve the symptoms. Medication can decrease the pain related to an outbreak and can shorten healing time. They can also decrease the total number of outbreaks. Drugs including Famvir, Zovirax, and Valtrex are among the drugs used to treat the symptoms of herpes. Warm baths may relieve the pain associated with genital sores.
How Painful Is Herpes Simplex?
Some people experience very mild genital herpes symptoms or no symptoms at all. Frequently, people infected with the virus don't even know they have it. However, when it causes symptoms, it can be described as extremely painful. This is especially true for the first outbreak, which is often the worst. Outbreaks are described as aches or pains in or around the genital area or burning, pain, or difficulty urinating. Some people experience discharge from the vagina or penis.
Oral herpes lesions (cold sores) usually cause tingling and burning just prior to the breakout of the blisters. The blisters themselves can also be painful.
Can Herpes Be Cured?
There is no cure for herpes simplex. Once a person has the virus, it remains in the body. The virus lies inactive in the nerve cells until something triggers it to become active again.
WebMD Medical ReferenceReviewed by Traci C. Johnson, MD on September 08, 2016
Sources© 2016 WebMD, LLC. All rights reserved.
Citation: Johnston C, Magaret A, Roychoudhury P, Greninger AL, Reeves D, Schiffer J, et al. (2017) Dual-strain genital herpes simplex virus type 2 (HSV-2) infection in the US, Peru, and 8 countries in sub-Saharan Africa: A nested cross-sectional viral genotyping study. PLoS Med 14(12): e1002475. https://doi.org/10.1371/journal.pmed.1002475
Academic Editor: Nicola Low, University of Bern, SWITZERLAND
Received: August 15, 2017; Accepted: November 20, 2017; Published: December 27, 2017
Copyright: © 2017 Johnston et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting Information files (S1 Data, S2 Data). HSV-2 genome sequences are available from GenBank (Accession numbers shown in S2 Table).
Funding: Funding for this work was provided by the National Institutes of Health/National Institute of Allergy and Infectious Diseases R21AI096058 and P01AI031731. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: Consultant: Glaxo SmithKline (DMK, AW), AiCuris (AM, AW), Amgen (AW), Biomedical Research Models (DMK), Merck (DMK), EASAI (DMK). Sponsored research: Sanofi Pasteur (DMK, CJ), Admedus Vaccines (DMK), Merck (DMK), Immune Design Corporation (AM, DMK, KRJ), Genocea (CJ, AW), Vical (CJ, AW, KRJ, DMK), Agenus (CJ, AW). Travel: Admedus Vaccines (AW). Stock Ownership: Merck (DMK), Amgen (DMK).
Abbreviations: CI, confidence interval; CMV, cytomegalovirus; HSV, herpes simplex virus; HSV-2, herpes simplex virus type 2; HTS, high-throughput sequencing; RR, risk ratio; SNP, single nucleotide polymorphism; UW-VRC, University of Washington Virology Research Clinic
Development of an effective herpes simplex virus type 2 (HSV-2) prophylactic vaccine is a global priority to improve sexual health [1,2]. Although several HSV-2 subunit vaccine candidates appeared effective in animal models, these vaccines have failed to prevent HSV-2 disease in humans in Phase III clinical trials, despite eliciting high levels of neutralizing antibody [3,4]. Knowledge of HSV-2 immunology has advanced with identification of B cell and T cell epitopes as well as identification of tissue-resident memory T cells; however, correlates of HSV-2 immunity in immunocompetent people have not been identified [5–9].
A key component to understanding an “effective” immune response is knowledge of whether naturally occurring HSV-2 infection is sufficient to prevent HSV-2 infection with a heterologous strain. Recently, vaccine candidates and other herpes simplex virus (HSV) products essentially presenting the entire HSV proteome to the immune system have entered clinical trials or have been approved by the US Food and Drug Administration, such that elicitation of coordinated T and B cell responses to diverse HSV targets is now potentially within reach. For example, the replication-incompetent HSV-2 vaccine candidate dl5-29 has completed a Phase I trial . The deletion of CD8 T cell immune evasion genes from the replication-competent HSV-1 oncolytic virus that is approved for melanoma therapy raises the possibility that whole virus vaccines might safely elicit responses that are stronger than those afforded by natural infection . Now that elicitation of diverse immune responses to HSV-2 is becoming possible, it is increasingly important to quantify the extent of protection afforded by HSV-2 infection against infection with a second strain.
In this study, we define shedding of 2 different HSV-2 strains at 2 different time points as “dual-strain infection.” This definition does not address whether strains were acquired simultaneously at the time of primary infection or sequentially (defined as “superinfection” in the HIV field) . HSV-2 dual-strain infection has been explored in prior studies with genotyping based on restriction length polymorphism (RFLP) analysis [13–15]. Later studies used PCR-based polymorphisms in regions with variable numbers of repeats; these studies were performed in a small number of people but showed striking differences in dual-strain infection in those who were HIV seronegative (1 of 8, 12.5%) and HIV seropositive (11 of 11, 100%) . There are no standardized methods for performing HSV-2 genotyping, and studies exploring dual-strain infection have seldom been performed using more modern techniques that are able to query a substantial proportion of the genome. To our knowledge, previous studies of HSV-2 dual-strain infection have also investigated relatively small numbers of participants.
We recently sequenced 38 HSV-2 genomes from genital swabs obtained from individuals in the US, Peru, and several countries in Africa . From these sequences, we identified single nucleotide polymorphisms (SNPs) that could best differentiate between samples to design a novel custom genotyping panel using an array-based genotyping assay. Such assays have previously been customized to type Salmonella typhi and Vibrio vulnificus, as well as Plasmodium falciparum [18–20]. To our knowledge, this is the first application of an array-based assay for HSV genotyping. We developed the custom genotyping platform to determine the prevalence of HSV-2 dual-strain infection and to identify risk factors for dual-strain infection. Women have a 2-fold increased risk of HSV-2 seropositivity compared to men, and people with HIV infection also have a higher rate of HSV-2 seropositivity than the general population [21,22]. We hypothesized that women, people with HIV infection, and people from regions with high seroprevalence of HSV-2 infection would have increased risk of HSV-2 dual-strain infection.
Written informed consent was obtained from all participants, and procedures were approved by the University of Washington Human Subjects Division.
We conducted a cross-sectional study, nested within genital HSV-2 natural history studies conducted at the University of Washington Virology Research Clinic (UW-VRC) between 1 January 1993 and 31 December 2014 and 2 HIV prevention clinical trials conducted in Peru and several African countries (HIV Prevention Trials Network [HPTN] 039, ClinicalTrials.gov NCT00076232, and the Partners in Prevention HSV/HIV Transmission Study, ClinicalTrials.gov NCT00194519) [23,24]. The eligibility criterion for this study was the availability of at least 2 genital swab specimens containing ≥105 copies HSV DNA/ml taken at least 1 day apart (S1 Fig). At minimum, 2 samples are required to estimate the prevalence of dual-strain infection because it is unlikely that 2 distinct strains would be shed at the same time and at the same location in high enough quantities to be differentiated from each other.
Of those eligible, people were selected to attempt to equally balance sex, to have 25% of the sample with HIV infection, and to have 25% from Africa and 25% from Peru and 50% from the US. Samples were collected a median of 5 months apart (IQR: 2–11 months); whenever possible, samples from the UW-VRC were prioritized based on longest length of time between sample collections. Baseline demographic and health information including sex, age, HIV status, number of sexual partners since initiation of sexual activity, type of sexual partnership (heterosexual or men who have sex with men), and continent of origin was collected at enrollment and included in the univariable and multivariable analysis.
Selection of SNPs for HSV-2 genotyping assay
SNPs in the HSV-2 genome were identified by performing high-throughput sequencing (HTS) of genital HSV-2 swabs from 38 people as previously described . Population-prevalent SNPs, defined as SNPs present in at least 10% and at most 90% of specimens, were evaluated for inclusion into the genotyping assay. To determine the optimal SNPs to differentiate between HSV-2 strains, a cluster analysis was performed by computing distance as an absolute difference between the sequences (Manhattan method) using “hclust” in R  (S1 Fig). The “FasTagger” function (version 3.0), which reduces the number of SNPs to distinguish sequences through evaluation of multilocus disequilibrium, was used to rank the SNPs according to their ability to distinguish sequences . This analysis identified 96 SNPs to diagnose HSV-2 strains as the same or different (S1 Table).
A custom array-based genotyping assay (GoldenGate, Illumina) was designed using the SNPs identified in S1 Table. DNA was extracted from genital samples using QIAamp DNA Blood Kit (Qiagen), with the following modifications: wash AW1 was omitted, and 2 washes of AW2 were performed. HSV PCR was performed as previously described , and samples underwent the genotyping assay as per manufacturer instructions. Briefly, samples were biotinylated and immobilized onto streptavidin-conjugated paramagnetic particles. Using the custom multiplex Oligo Pool Assay (Illumina), oligonucleotides were hybridized to DNA, and allele-specific extension and ligation was performed. The extended and ligated products formed a template that was transferred to a PCR mixture and amplified using universal primers. Next, the strand containing fluorescent signal was isolated and hybridized to Universal BeadChips and subsequently imaged on the Illumina iScan+.
SNPs were included in the analysis of dual-strain infection if they had a valid call in over 90% of all of the samples included in the study. At least 4 negative control samples were included on each plate. Clinical samples that did not have resolved calls in 9 or more SNPs were considered failed specimens and were excluded from the analysis (S1 Fig).
For individuals who had ≥5 HSV-2 mismatches between paired samples based on the array, we confirmed that the samples were from the same participant using the Investigator DIPplex Kit (Qiagen), which performs multiplex amplification of 30 polymorphic human INDELs and has been validated for human identification , according to manufacturer’s instructions. If samples could not be confirmed to be from the same person with this test, they were excluded from the analysis (S1 Fig).
For the subset of individuals who met our criteria for dual-strain infection by the array-based genotyping assay, HTS of HSV-2 genomes was performed using the Illumina platform. DNA was fragmented using the Kapa HyperPlus Kit, and enrichment was performed using a custom IDT xGen oligonucleotide panel tiling the HSV-2 HG52 reference genome (NC_001798). Enriched pools of dual-indexed libraries were sequenced on an Illumina MiSeq using 2 × 300-bp sequencing runs. Reads were processed as previously described . Briefly, raw reads were adapter- and quality-trimmed using BBDuk from the BBMap package version 36  and de novo assembled using SPAdes version 3.9 . Assembled scaffolds were mapped to the HSV-2 SD90 reference genome using Mugsy , gaps between scaffolds were filled with mapped reads, and a consensus sequence was constructed from the final merged alignment using a custom R script . Allele frequencies were computed using LoFreq .
Dual-strain infection prevalence sampling adjustment
We conducted a set of simulations to assess our ability to detect dual-strain infection with only 2 samples per person. True numbers of infecting strains were simulated for hypothetical people using a zero-truncated Poisson distribution indexed by λ; λ is a parameter that increases with the average number of infecting strains. We then randomly selected a single strain from each person, twice, to mimic the clinical experiment (code available online at https://github.com/dbrvs/goldengate_model). The resulting simulated data were compared with the experimental data to determine the true dual-strain infection frequency that best described the observed frequency. The sampling-adjusted estimate of dual-strain infection is subject to these assumptions: (1) accuracy of the zero-truncated Poisson distribution, which is akin to assuming a relatively even risk profile across populations, and (2) equal relative abundance, meaning that all infecting strains are detectable at the same frequency. Departures from the second assumption would inflate the adjusted dual-strain frequency further.
Bayesian probabilities were computed to determine whether the selected SNPs could identify dual-strain infection. Bayes’s rule was used to estimate correct identification of identical/nonidentical sequences, with the following notation and equations. Let M indicate match at all SNPs (~M = mismatch) and I indicate that 2 sequences are truly identical at all loci (~I = not identical). Using standard Bayesian conditional probabilities for computing positive predictive and negative predictive values from prevalence of dual-strain infection p(~I), sensitivity of SNPs for dual-strain infection p(~M|~I), and specificity p(M|I), we compute the probability of correctly identifying identical sequences from matching SNPs p(I|M) and the probability of correctly identifying nonidentical sequences from mismatched SNPs p(~I|~M) using the following equations.
The estimate for dual-strain infection was based on the number of pairs that met criteria for dual-strain infection divided by the total sample. The confidence interval (CI) for this estimate comes from the standard formula for variability of a binomial proportion.
Phylogenetic trees were created using the concatenated UL_US regions, and maximum likelihood with bootstrapping (1,000 replicates) was used to compute support values as previously described .
Although we initially hypothesized 10% prevalence of dual-strain infection and planned to include 600 participants in the study, with a dual-strain infection prevalence of 5% and 400 participants, we had 89% power to detect a 3-fold increased risk of dual-strain infection in women and 81% power to detect a 3-fold increased risk of HSV-2 dual-strain infection based on HIV status and continent of origin. Poisson regression was used to assess potential univariable and multivariable associations of participant characteristics with dual-strain infection. Terms for interactions between HIV status and continent and HIV status and sex were tested. The initial multivariable model included sex, age, continent, lifetime number of sexual partners, HIV status, type of sexual partnership, and time between sample collections, with variables removed through backwards elimination. In response to requests from an anonymous reviewer, we also stratified the multivariable model by HIV status and performed a sensitivity analysis including 8 pairs of samples that were excluded due to failure of the assay to confirm that the samples were from the same person. p-Values ≤ 0.05 were considered statistically significant. This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines (S1 Checklist).
Samples to determine prevalence of dual-strain infection
Overall, 1,152 samples were selected for genotyping, including 1,093 clinical samples from 537 people, with 59 negative controls (S1 Fig). Of the clinical samples, 918 specimens from 459 people met the criteria of having valid calls at a minimum of 90% of HSV-2 loci in the array and having a paired specimen; 8 pairs that appeared superinfected were removed from the analysis because they could not be confirmed to be from the same person (S1 Fig). Of the 918 swabs, 638 (69.5%) were collected on days on which a lesion was present. The remainder of swabs were collected during asymptomatic shedding episodes. The baseline characteristics of the selected group are shown in Table 1; 213 (46%) were men, with a median age of 34 years (IQR: 27–44). Overall, 272 (59%) were from the US, 59 (13%) were from Peru, 128 (28%) were from 1 of 8 African countries (including Botswana, Cameroon, Kenya, South Africa, Tanzania, Uganda, Zambia, and Zimbabwe). Infection with HIV was present in 130 (28%) people. The median lifetime number of sexual partners was 11 (IQR: 3–32). Of 438 people who reported type of sexual partnership, 382 (65%) identified as heterosexual, and 155 (35%) were men who had sex with men.
Identification of SNPs for genotyping platform and validation
To obtain information for SNP selection, we sequenced HSV-2 DNA collected from genital swabs from 38 people in the US, Peru, and several African nations as described above . From these sequences we identified 456 population-prevalent SNPs and prioritized SNPs that could best distinguish strains from one another for creation of a high-throughput genotyping assay (S2 Fig). The SNPs selected for development of the custom genotyping assay are shown in S1 Table. Eleven (11.5%) of the 96 loci selected failed the prespecified quality criteria and were subsequently excluded from analysis of dual-strain infection, leaving 85 loci for analysis. We estimated that based on the prevalences of these 85 SNPs and assuming a dual-strain infection frequency of 10% and a call error rate of 1%, there was a >99% probability of correcting calling identical sequences and a 92% probability of correctly identifying nonidentical sequences.
To confirm that the array-based genotyping assay correctly identified HSV-2 sequences, we determined whether the genotype matched the result from HTS at each locus in 5 samples that underwent both HTS and array-based genotyping. Among these 5 samples, there were matches at all positions with valid results for both methods (a total of 449 loci) and no mismatches.
To confirm that these selected loci could distinguish between strains, we used 70 HSV-2 full-length or partial genetically nonidentical HSV-2 sequences available in GenBank [17,34] and found that these 85 loci could distinguish all but 2 pairs of strains (out of 2,415 combinations) (99.9% specificity). We evaluated the number of mismatches among sequences collected from different people, and found that most samples had at least 5 mismatches (1,905 [99.2%] of 1,920 observations) and that the median number of mismatches between unrelated pairs was 23 (IQR: 19–27). Because fewer than 1% of samples had <5 mismatches, and due to concern that paired samples with fewer than 5 mismatches could have represented within-host evolution or sequencing error, at least 5 mismatches were required between pairs to diagnose dual-strain infection.
Determination of dual-strain infection based on number of SNP mismatches between paired specimens
Of the 459 participants with paired samples, 418 (91%) participants had identical SNPs in the paired specimens. The remaining 41 pairs were mismatched at a median of 3 SNPs (IQR: 1–28). As shown in Fig 1, 14 (34%) differed at only 1 locus. Eighteen pairs had ≥5 mismatches and met our prespecified criteria for dual-strain infection. Among these 18 pairs, the median number of mismatches was 18 (IQR: 11–21). For each pair that appeared to have mismatched HSV-2 strains, we confirmed that the specimens came from the same person using a multiplex amplification kit developed for human identification.
Fig 1. Histogram of the number of mismatches using a custom genotyping assay for each of the 41 pairs with any mismatches.
Pairs with ≥5 mismatched SNPs were considered superinfected; those with 1–3 mismatched SNPs were not subject to confirmation by high-throughput sequencing.
Confirmation of dual-strain infection using HTS with oligonucleotide enrichment
For 18 pairs that appeared to have different HSV-2 strains present in the 2 samples, we performed DNA oligonucleotide enrichment followed by HTS (S2 Table). High-quality sequences were obtained from 14 pairs; the remaining 4 pairs were not able to be sequenced but were retained in the analysis as superinfected pairs. We also confirmed mismatches at array sites using HTS data by determining whether the majority base at each array site for paired samples was a match (S3 Fig). For one pair (Pair 3) we found that the SNP mismatches identified by the array were not found in the full genome sequence, suggesting that one of the samples in this pair was contaminated or mislabeled, and therefore we removed this pair from the analysis of dual-strain infection. For the remaining 13 pairs, we observed a median of 274 mismatched SNPs in the genomic sequence (range 129–413). Phylogenetic analysis revealed that most paired but unique specimens did not cluster together on the tree, supporting that the sequences represent 2 different strains rather than within-host evolution (Fig 2). The median Tamura–Nei distance between the pairs was 0.0023 (IQR: 0.0020–0.0025). We explored whether minor variants representing the strain found at one time point could be found within the dominant strain of the other time point. We found minor alleles at frequencies > 2% at array sites in 10 out of 14 pairs, but we were unable to consistently detect signatures of the other strain at these sites.
Fig 2. Phylogenic tree of paired specimens that underwent oligonucleotide enrichment and high-throughput sequencing.
The concatenated UL_US regions were used to create the phylogenetic tree, using maximum likelihood. Bootstrapping with 1,000 replicates was used to compute support values. Paired specimens are indicated by number with “a” and “b.” Pair 3, which was found to be incorrectly identified as superinfected using the array, was excluded from the tree.
Estimated prevalence of and risk factors for dual-strain genital HSV-2 infection
Overall, using the genotyping assay we identified infection with 2 different strains in 17 (3.7%) of 459 people (prevalence = 3.7%, 95% CI = 2.0%–5.4%), with dual-strain infection confirmed using HTS in 13 persons. Using simulated data that account for the possibility of detecting a single strain by chance even when multiple infecting strains are present, we inferred the underlying prevalence of dual-strain infection to be ~7% (S4 Fig).
In univariable analysis, we found that sex, age, lifetime number of sexual partners, and type of sexual partnership (heterosexual versus men who have sex with men) were not associated with dual-strain infection (Table 2). However, the univariable analysis revealed that people from Peru and from Africa had a 6.9-fold (95% CI = 1.2–40.3) and 12.8-fold (95% CI = 2.9–55.7) increased risk of dual-strain infection, respectively, compared to people from the US. People with HIV infection had a 6.1-fold increased risk of dual-strain infection (95% CI = 2.2–17.0) compared with HIV-negative people. In a multivariable model including continent of origin and HIV serostatus, collection from Africa (risk ratio [RR] = 9.20, 95% CI = 2.05–41.32) and HIV seropositivity (RR = 4.06, 95% CI = 1.42–11.56) remained significantly associated with HSV-2 dual-strain infection. In the multivariable analysis, we tested the interaction between HIV status and continent and did not find a significant interaction. However, to exclude the possibility that the higher frequency of dual-strain infection in Africa could be due to residual confounding by HIV infection, we also stratified the multivariable analysis by persons with and without HIV infection; the RR for being from Africa was 8.57 among persons without HIV infection (p = 0.06) and 9.52 among persons with HIV infection (p = 0.003). In a sensitivity analysis including 8 pairs that appeared superinfected but were excluded due to inability to confirm they were from the same person, nearly identical findings were demonstrated in the multivariable model, although the strength of the association was attenuated (collection from Africa: RR = 4.38, 95% CI = 1.69–11.36; HIV seropositivity: RR = 2.81, 95% CI = 1.25–6.34) (S3 Table).
In this report, we systematically studied the prevalence of HSV-2 dual-strain infection using paired genital swab samples collected at 2 different time points from 459 people in 3 continents. Among 18 pairs of samples that appeared to have different strains at the 2 time points by genotyping, we definitively confirmed that 2 different strains were shed at different time points in 13 people using whole genome sequencing, and were unable to perform confirmatory sequencing in 4 pairs. These results revealed that the prevalence of HSV-2 dual-strain infection was 3.7%, with sampling-adjusted estimates indicating that the true prevalence may be 7%. In multivariable analysis, dual-strain infection was associated with people who were from Africa and people with HIV infection. The finding that HSV-2 dual-strain infection was relatively rare in this sample may indicate that the natural immune response is usually sufficient to protect against infection with a second strain of HSV-2. These data suggest that a vaccine format that elicits a breadth and level of specific immunity that meets, or exceeds, that achieved by natural genital HSV-2 infection may be efficacious in preventing infection with wild-type virus.
We demonstrated that population-prevalent SNPs identified using HTS could be used to identify dual-strain infection using a custom genotyping tool. The ability to use genomic sequences to determine which high-yield SNPs to use for genotyping is just one application of HTS, which has the potential to significantly advance our understanding of the pathogenesis of HSV-2 infection. In this work, we built a genotyping platform and validated it using HTS. While rapid genotyping methods are in a state of flux characterized by improvements in cost, throughput, and specimen requirement, it is important to validate each candidate method. Although the SNPs selected for genotyping in this analysis might not as reliably differentiate strains from people from other geographic areas, the rapidly growing database of full-length and partial HSV-2 genomes will facilitate future genomic analyses of this type [17,34–38].
In this study, we were not able to determine whether people with dual-strain infection acquired the 2 strains at the time of the initial HSV-2 acquisition, or whether they acquired the strains sequentially. However, based on HTS studies performed to date, both in this sample and prior studies, simultaneous shedding of 2 strains was detected in only 1 (1.8%) of 55 people studied. The low frequency of dual-strain shedding within individuals detected to date suggests to us that acquisition of 2 strains simultaneously from 1 exposure would be less likely than acquisition of 1 strain followed by a second strain at the time of a second exposure. Only a prospective study of a cohort enrolled during primary HSV-2 infection could adequately address this issue. Studies of full-length HSV-1 and HSV-2 sequences have revealed evidence for pervasive HSV-2 × HSV-2 and HSV-1 × HSV-2 inter-strain recombination, implying dual-strain infection of individuals, and indeed of single cells, with 2 strains of HSV-2 or simultaneous infection with HSV-1 and HSV-2 [37,39].
Dual-strain infection has been explored with other herpesviruses using both classic and newer sequencing-based methods to determine the presence of multiple strains. Infection with a second, heterologous cytomegalovirus (CMV) strain has been demonstrated in nearly 1/3 of healthy, young, previously pregnant US women followed over a 3-year period, based on development of new antibody formation against a polymorphic epitope , but the study did not identify risk factors for infection with a second strain. In addition, data consistent with mixed CMV infection were found in nearly half of 28 newborns with congenital CMV infections . Whole genome sequencing of longitudinally collected specimens from congenitally CMV-infected infants has demonstrated mixed-strain CMV infection in 1/3 of patients and suggests that maternal reinfection occurs frequently [42,43]. Infection with 2 strains of varicella zoster virus has also been demonstrated in case reports . The prevalence of HSV-2 dual-strain infection found in the present analysis, 3.7%, was much lower than the prevalence of mixed-strain CMV infection in healthy US women . The much longer follow-up period in the CMV study in young women suggests that the risk of superinfection may be cumulative over time.
To our knowledge, this study is the largest investigation of HSV-2 dual-strain infection to date, and we utilized a novel genotyping strategy to detect dual-strain infection. Initial studies of HSV-2 genotyping using restriction length polymorphisms to genotype specimens indicated that dual-strain infection was possible [13–15]. Using PCR-based genotyping methods based on DNA repeats, Roest et al. identified evidence of dual-strain infection in 11 of 11 people with HIV infection and 1 of 8 people without HIV infection . Burrel et al. characterized microsatellite repeats within the HSV-2 genome to develop a PCR-based genotyping assay based on polymorphisms within 12 microsatellite regions and were able to differentiate 56 strains from Western Europe and West Africa . In a previous study in which we performed HTS on paired samples from 8 people, we found HSV-2 dual-strain infection in 2 people with HIV infection . However, with such small numbers of participants, it is difficult to make definitive conclusions about risk factors associated with dual-strain infection.
In this large study population selected from longitudinal natural history studies and international clinical trials we found that HIV infection is a significant risk factor for HSV-2 dual-strain infection, with 4.0-fold increased risk compared to HIV-seronegative people. As the participants with HIV infection in this sample had CD4 counts > 350 cells/mm3 at enrollment into the studies, it is unlikely that severe immunocompromise was responsible for the increased risk of dual-strain infection. HSV-2 is a prevalent infection in HIV-seropositive people, and the increased risk of HSV-2 dual-strain infection in this population may be a result of increased risk of sexual exposure to heterologous HSV-2 strains [22,24]. We were not able to detect an independent contribution of lifetime number of sexual partners. Prospective studies of sexually active people with and without HIV infection are required to determine if HIV infection in the absence of overt immune compromise, or specific sexual practices, are independent risk factors for HSV-2 dual-strain infection.
This study had several important limitations. Due to the cross-sectional design of this study, we were able to determine the prevalence, but not the incidence, of dual-strain infection; the incidence would provide a better estimate of the effectiveness of naturally occurring HSV-2 immunity against reinfection with a second strain of virus. Importantly, prospective cohort data would allow researchers to differentiate between acquisition of 2 strains simultaneously during primary infection versus sequential infection of a second strain after new exposure. We did not have information about all sexual partners in the interim between sample collections, and therefore whether people were at risk for acquiring dual-strain infection during the follow-up period is unknown. In prospective cohorts, associations between incidence of HSV-2 dual-strain infection and risks of exposure, including number of sexual partners and sexual encounters, can be ascertained. In addition, we were not able to determine whether HSV-2 dual-strain infection results in any difference in clinical HSV-2 presentation, such as increased rates of mucosal shedding or genital ulcer disease, but this would be an area of interest for future studies. Due to many specimens failing our strict quality criteria for the genotyping assay, we had a smaller sample size in the analysis than originally planned. There may have been small differences in the risk of dual-strain infection between groups, for instance women and men, that we were underpowered to detect. Due to the assay design, we were unable to test samples with <5 log10 copies HSV DNA/ml; it is possible that additional strains would be shed only at lower quantities, resulting in an underestimate of dual-strain infection. Dual-strain infection prevalence may differ in populations from different parts of the world or in populations with high rates of sexual exposure to HSV-2 infection. The increased risk shown in the African population may be a reflection of higher HSV-2 seroprevalence in this population, and therefore higher risk for exposure to different strains , or may be because of bias due to defining dual-strain infection based on array-based SNP genetic distance: HSV strains isolated from African populations show a higher amount of genetic distance from each other; thus, we may be undercounting dual-strain infection in other geographical areas . The sampling-adjusted estimate of dual-strain infection assumes that the zero-truncated Poisson distribution is accurate and that strains are detectable at the same frequency. To evaluate departures from the zero-truncated Poisson assumption, we are exploring the impact of varying HSV-2 acquisition risk within the study sample.
In summary, we measured the frequency of HSV-2 dual-strain infection in a large sample of people from around the world and showed that infection with more than 1 strain was rare in this sample. Understanding the frequency of and risk factors for HSV-2 dual-strain infection is important for the future design of prophylactic vaccine studies. Based on these results, we hypothesize that generation of a broad immune response to HSV-2 infection, similar to naturally induced immunity, could be protective against infection with a second strain. Future studies using genomics and genotyping may lead to further insights into HSV-2 biology that bring us closer to the development of a successful prophylactic HSV-2 vaccine.
- 1. Gottlieb SL, Johnston C. Future prospects for new vaccines against sexually transmitted infections. Curr Opin Infect Dis. 2017;30:77–86. pmid:27922851
- 2. Johnston C, Gottlieb SL, Wald A. Status of vaccine research and development of vaccines for herpes simplex virus. Vaccine. 2016;34:2948–52. pmid:26973067
- 3. Belshe RB, Heineman TC, Bernstein DI, Bellamy AR, Ewell M, van der Most R, et al. Correlate of immune protection against HSV-1 genital disease in vaccinated women. J Infect Dis. 2014;209:828–36. pmid:24285844
- 4. Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med. 2012;366:34–43. pmid:22216840
- 5. Cairns TM, Huang Z-Y, Gallagher JR, Lin Y, Lou H, Whitbeck JC, et al. patient-specific neutralizing antibody responses to herpes simplex virus are attributed to epitopes on gD, gB, or both and can be type specific. J Virol. 2015;89:9213–31. pmid:26109729
- 6. Cairns TM, Huang ZY, Whitbeck JC, Ponce de Leon M, Lou H, Wald A, et al. Dissection of the antibody response against herpes simplex virus glycoproteins in naturally infected humans. J Virol. 2014;88:12612–22. pmid:25142599